Tocagen is developing first-in-class, broadly applicable product candidates for the treatment of cancer using our cancer-selective gene therapy platform built on retroviral replicating vectors, or RRVs, initially for patients with recurrent high grade glioma, or HGG.
Our broadly applicable product candidates are designed to activate a patient’s immune system against their own cancer from within.
At the core of our approach is a gene therapy platform that utilizes RRVs, which are designed to selectively deliver therapeutic genes into the DNA of cancer cells. Our proprietary platform is designed to fight cancer through a combination of mechanisms without the autoimmune toxicities that patients commonly experience with other treatments. In other words, our technology is designed to combat cancer with fewer side effects, keeping patients’ healthy tissue intact while the tumor is destroyed.
Tocagen exists for the patients. Our hope is that even the most aggressive forms of cancer can be safely and effectively controlled, and each day we strive to turn that bold vision into reality.
Tocagen has received grant support from leading brain cancer foundations, including Accelerate Brain Cancer Cure (ABC2), National Brain Tumor Society (NBTS), American Brain Tumor Association (ABTA), Musella Foundation and Voices Against Brain Cancer (VABC).